Table 1 Baseline disease characteristics by background AD therapy
Placebo | Neflamapimod | |||
|---|---|---|---|---|
AD therapy (n = 51) | No AD therapy (n = 32) | AD therapy (n = 46) | No AD therapy (n = 32) | |
Age | 73 (7.8) | 72.1 (5.9) | 72.2 (6.8) | 68.9 (5.6) |
Gender (% female) | 45.1 | 62.5 | 47.8 | 46.9 |
ApoE4 (% positive) | 66.7 | 71.9 | 67.4 | 78.1 |
HVLT-R Total Recall | 13.4 (4.5) | 18.3 (4.9) | 14.8 (5.1) | 18.6 (6.9) |
HVLT-R Delayed Recall | 1.8 (2.1) | 4.0 (3.3) | 2.2 (2.4) | 4.7 (4.0) |
WMS Immediate & Delayed Recall | 58.1 (21.8) | 84.2 (34.1) | 61.7 (25.0) | 92.6 (42.0) |
CDR sum of boxes | 3.7 (1.6) | 2.4 (1.5) | 3.4 (1.4) | 2.6 (1.0) |
MMSE | 22.7 (2.4) | 25.2 (2.7) | 22.9 (2.5) | 25.1 (2.3) |
CSF Aβ40 | 10583 (3340) | 10783 (3162) | 11099 (2926) | 11259 (3465) |
CSF Aβ42 | 545 (155) | 562 (194) | 556 (138) | 602 (196) |
CSF p-tau181 | 35.5 (14.2) | 30.9 (11.0) | 37.6 (15.1) | 33.4 (14.4) |
CSF total tau | 360 (126) | 316 (97) | 378 (132) | 337 (116) |
CSF neurogranin | 477 (238) | 427 (160) | 510 (224) | 469 (161) |
CSF NfL | 1456 (640) | 1230 (694) | 1586 (760) | 1257 (530) |